Age, leukocyte counts, BAALC, and MN1 gene expressions as well as high copy numbers of RUNX1-RUNXT1 or CBFB-MYH11 after induction chemotherapy are useful tools to predict the outcome and should be considered for risk-adapted therapy..     ///    CBFB-MYH11 n?=?76) were prospectively enrolled into two consecutive CETLAM protocols at 19 Spanish institutions.     ///    "In multivariate analyses, leukocyte count above 20????10(9) /L, BAALC over-expression, and high copy numbers of RUNX1-RUNXT1 or CBFB-MYH11 after induction chemotherapy (CT) led to increased relapse rate. "